Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IDegLira (REMITiDegLira)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03862716
Recruitment Status : Recruiting
First Posted : March 5, 2019
Last Update Posted : September 16, 2021
Sponsor:
Collaborator:
Novo Nordisk A/S
Information provided by (Responsible Party):
Population Health Research Institute

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The purpose of the study is to determine whether in patients with early type 2 diabetes, a short-term intensive metabolic intervention comprising IDegLira, metformin, and lifestyle approaches will be superior to standard diabetes therapy in achieving sustained diabetes remission.

Condition or disease Intervention/treatment Phase
Type 2 Diabetes Mellitus Drug: IDegLira Drug: insulin degludec Drug: Metformin Behavioral: Lifestyle Therapy Phase 3

Detailed Description:
This is a multicentre, open-label, randomized controlled trial in 160 patients with recently-diagnosed T2DM. Participants will be randomized to 2 treatment groups: (a) a 16-week course of treatment with IDegLira, metformin and lifestyle therapy, and (b) standard diabetes therapy, and followed for a total of 68 weeks (1 year and 4 months). In all participants with HbA1C<7.3% at the 16 week visit, glucose-lowering medications will be discontinued and participants will be encouraged to continue with lifestyle modifications and regular glucose monitoring. Participants with HbA1C ≥ 7.3% at this visit or who experience hyperglycemia relapse after stopping drugs will receive standard glycemic management as informed by the current Canadian Diabetes Association clinical practice guidelines.
Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 160 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IDegLira (REMIT IDegLira): A Randomized Controlled Trial
Actual Study Start Date : April 23, 2019
Estimated Primary Completion Date : December 31, 2021
Estimated Study Completion Date : May 31, 2023

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Intervention
Drug: IDegLira - sc injection; Drug: metformin - oral administration; Drug: insulin degludec - sc injection; Behavioral: lifestyle therapy, diet and exercise
 Drug: IDegLira
Dose is titrated to achieve fasting normoglycemia
Other Name: insulin degludec / liraglutide

Drug: insulin degludec
In those who need additional insulin or who cannot tolerate IDegLira, insulin degludec will be used. Dose is titrated to achieve fasting normoglycemia.

Drug: Metformin
Dose is titrated to 2000 mg per day or maximal tolerated dose

Behavioral: Lifestyle Therapy
Lifestyle intervention includes individualized dietary and exercise advice targeting at least 5% weight loss with frequent visits and coaching for goal reinforcement, behavior modification and problem-solving
Other Name: diet and exercise
No Intervention: Standard Care
Standard glycemic care as informed by the current clinical practice guidelines


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Proportion of participants achieving drug-free diabetes remission [ Time Frame: 28 weeks after randomization ]
    Drug-free diabetes remission is defined as HbA1C < 6.5 % off glucose-lowering agents for at least 12 weeks.


Secondary Outcome Measures :
  1. Proportion of participants achieving drug-free diabetes remission [ Time Frame: 28 weeks, 40 weeks, 52 weeks and 68 weeks after randomization ]
  2. Proportion of participants achieving drug-free normoglycemia [ Time Frame: 28 weeks, 40 weeks, 52 weeks and 68 weeks after randomization ]
    defined as HbA1C < 6.0% off glucose-lowering agents for at least 12 weeks.

  3. Proportion of participants achieving drug-free diabetes regression [ Time Frame: 28 weeks, 40 weeks, 52 weeks and 68 weeks after randomization ]
    defined as HbA1C <7.0% off glucose-lowering agents for at least 12 weeks.


Other Outcome Measures:
  1. the time interval from randomization until any glucose lowering drug is restarted or relapse of hyperglycemia [ Time Frame: Up to week 68 ]
  2. the time interval from the 16 week visit (i.e. when glucose lowering drugs are to be stopped) until any glucose lowering drug is restarted or relapse of hyperglycemia [ Time Frame: Up to week 68 ]
  3. the change in HbA1c [ Time Frame: 16, 28, 40, 52 and 68 week visit as well as the overall change ]
  4. the change in weight [ Time Frame: 16, 28, 40, 52 and 68 week visit as well as the overall change ]
  5. the change in waist circumference [ Time Frame: 16, 28, 40, 52 and 68 week visit as well as the overall change ]
  6. the change in hip circumference [ Time Frame: 16, 28, 40, 52 and 68 week visit as well as the overall change ]
  7. the change in body mass index [ Time Frame: 16, 28, 40, 52 and 68 week visit as well as the overall change ]
  8. the change in coefficient of variation over 2 weeks (defined as 4-8 mmol/l), based on up to 2 weeks of Abbott Freestyle Libre ProTM sensor wear [ Time Frame: from randomization until the 6, 16, 28 and 52 week visit ]
  9. the change in interquartile range over 2 weeks (defined as 4-8 mmol/l), based on up to 2 weeks of Abbott Freestyle Libre ProTM sensor wear [ Time Frame: from randomization until the 6, 16, 28 and 52 week visit ]
  10. the change in time range over 2 weeks (defined as 4-8 mmol/l), based on up to 2 weeks of Abbott Freestyle Libre ProTM sensor wear [ Time Frame: from randomization until the 6, 16, 28 and 52 week visit ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   30 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. men and women aged 30-80 years;
  2. T2D diagnosed within 5 years
  3. stable T2D drug regimen in the 8 weeks before randomization;
  4. HbA1c 6.5-9.5% on no glucose lowering drugs, or 6.5%-8.0% on up to 2 glucose lowering drugs;
  5. body mass index ≥ 23 kg/m2;
  6. ability and willingness to perform self-monitoring of capillary blood glucose (SMBG);
  7. willingness to wear a continuous glucose monitor on at least 3 occasions;
  8. ability and willingness to self-inject IDegLira and insulin;
  9. provision of informed consent.

Exclusion Criteria:

  1. current use of insulin therapy;
  2. history of hypoglycemia unawareness, or severe hypoglycemia requiring assistance;
  3. history of end-stage renal disease or eGFR<45 mL/min/1.73 m2 by MDRD formula;
  4. active liver disease or elevated alanine transferase (ALT) levels ≥ 2.5 times the upper limit of normal at the time of enrolment;
  5. history or clinical suspicion of pancreatitis or medullary thyroid cancer;
  6. diagnosis or first degree relative with Multiple Endocrine Neoplasia Type 2 (MEN2);
  7. history of diabetic retinopathy requiring photocoagulation, injection therapy or vitrectomy;
  8. history of cardiovascular disease (unless cleared for a moderate intensity exercise program by a specialist) including: i. acute coronary syndrome, hospitalization for unstable angina, myocardial infarction, or revascularization with coronary artery bypass grafting or percutaneous coronary intervention; ii. peripheral vascular disease, valvular heart disease, cardiomyopathy, aortic dissection, tachyarrhythmias, bradyarrhythmias, prior stroke or TIA; iii. prior hospitalization for heart failure; or iv. ECG findings concerning for ischemic heart disease (i.e. pathological Q-waves, ST-segment-T-wave abnormalities in contiguous leads, left anterior hemiblock, left bundle branch block, second or third degree atrioventricular block).
  9. history of any disease requiring frequent intermittent or continuous systemic glucocorticoid treatment;
  10. history of bariatric surgery, or planned bariatric surgery in the next 1.5 years;
  11. history of any major illness with a life expectancy of < 3 years;
  12. history of injury or any other condition that significantly limits participant's ability to achieve moderate levels of physical activity;
  13. excessive alcohol intake, acute or chronic;
  14. currently pregnant, or breastfeeding, or not using a reliable method of birth control for the duration of the trial in all females with childbearing potential;
  15. inability to take insulin degludec, liraglutide or metformin.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03862716


Contacts
Layout table for location contacts
Contact: Stephanie Hall 905-521-2100 ext 40667 stephanie.hall@phri.ca

Locations
Layout table for location information
Canada, Alberta
University of Calgary Recruiting
Calgary, Alberta, Canada, T2T 5C7
Contact: Ron Sigal, MD    403-955-8107    rsigal@ucalgary.ca   
University of Alberta Not yet recruiting
Edmonton, Alberta, Canada, T6G 2E1
Contact: Caroline Lyster    780-248-1770    clyster@ualberta.ca   
Canada, Nova Scotia
Nova Scotia Health Authority Recruiting
Halifax, Nova Scotia, Canada, B3H 1V7
Contact: Blaine Gallant, BScN    902-473-3299    blaine.gallant@nshealth.ca   
Canada, Ontario
McMaster University Recruiting
Hamilton, Ontario, Canada
Contact: Zubin Punthakee, MD    905-525-9140 ext 22205    smithad@mcmaster.ca   
Contact: Ada Smith         
St. Joseph's Hospital Recruiting
London, Ontario, Canada, N6A 4V2
Contact: Tamara Spaic, MD       tamara.spaic@sjhc.london.on.ca   
Western University Recruiting
London, Ontario, Canada, N6G 2M1
Contact: Stewart Harris, MD    519-661-2111    Stewart.Harris@schulich.uwo.ca   
LMC Manna Research Not yet recruiting
Oakville, Ontario, Canada, L6M 1M1
Contact: Yaw Twum-Barima, MD    905-337-0040    oakvilleresearch@lmc.ca   
The Ottawa Hospital Not yet recruiting
Ottawa, Ontario, Canada, K1Y 4E9
Contact: Heather Lochnan, MD       hlochnan@toh.ca   
Sponsors and Collaborators
Population Health Research Institute
Novo Nordisk A/S
Investigators
Layout table for investigator information
Principal Investigator: Zubin Punthakee, MD McMaster University
Study Chair: Hertzel Gerstein, MD McMaster University
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Population Health Research Institute
ClinicalTrials.gov Identifier: NCT03862716    
Other Study ID Numbers: REMITiDegLira
First Posted: March 5, 2019    Key Record Dates
Last Update Posted: September 16, 2021
Last Verified: September 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Population Health Research Institute:
Diabetes
IDegLira
Metformin
Insulin
 Diet
Excercise
Lifestyle
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Insulin
Insulin, Globin Zinc
Metformin
 Liraglutide
Insulin, Long-Acting
Xultophy
Hypoglycemic Agents
Physiological Effects of Drugs
Incretins
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists